A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications
4 affiliations
- 1Department of Pathology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
- 2Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
- 3Department of Pathology, Temple University, Philadelphia, PA 19140, USA
- 4Cancer Signaling and Microenvironment Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Abstract
Complex molecular alterations in cancers influence tumor biology, therapeutic response, and resistance. We report a case of cutaneous melanoma demonstrating extensive intratumoral heterogeneity with important clinical implications. A 77-year-old man with stage IIA cutaneous melanoma developed an isolated nodal recurrence one year after resection. Comprehensive next-generation sequencing of the metastatic lesion revealed an uncommon genomic profile consisting of a class 3 BRAF Y472V mutation, two NF1 loss-of-function mutations, and two concurrent KIT mutations: a dominant, potentially targetable K642E mutation and a low-frequency D816V mutation associated with resistance to tyrosine kinase inhibitors. The tumor exhibited a high tumor mutational burden and microsatellite stability. The patient received neoadjuvant nivolumab plus relatlimab followed by surgical resection, achieving complete pathologic response. Repeat sequencing of the resected specimen demonstrated complete molecular clearance of all previously detected variants. This case illustrates the value of comprehensive genomic profiling in revealing biologically complex melanoma with coexisting driver and resistance-associated alterations. The presence of a treatment-naïve KIT resistance mutation suggests preexisting subclonal heterogeneity that may influence future targeted therapy, while high tumor mutational burden and NF1 loss may have contributed to the excellent response to immune checkpoint blockade.
Related
- NRAS Mutations in Different Melanoma Histotypes: Molecular and Clinical Implications
- Intratumoral microbiota heterogeneity and Bifidobacterium abundance are linked to very early recurrence in hepatocellular carcinoma
- Translated Circular RNAs in Glioblastoma: Emerging Regulators of Tumor Progression, Molecular Heterogeneity and Therapeutic Resistance
- Circular RNAs in tumor biology and immunology: molecular mechanisms and therapeutic implications
- MICAL2 as a key effector of β-catenin signaling driving melanoma progression and therapeutic resistance
BibTeX
@article{tan2026complex,
title = {{A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications}},
author = {Yinfei Tan and Giuliana G. Berardi and Tingwei Guo and Anjali Seth and Anthony J. Olszanski and Hong Wu and Y. Lynn Wang},
journal = {International Journal of Molecular Sciences},
year = {2026},
month = nov,
doi = {10.3390/ijms27219870},
url = {https://www.mdpi.com/1422-0067/27/21/9870},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - A Complex Molecular Profile in Melanoma: Intratumoral Heterogeneity and Therapeutic Implications
AU - Yinfei Tan
AU - Giuliana G. Berardi
AU - Tingwei Guo
AU - Anjali Seth
AU - Anthony J. Olszanski
AU - Hong Wu
AU - Y. Lynn Wang
PY - 2026
DA - 2026/11/04
JO - International Journal of Molecular Sciences
DO - 10.3390/ijms27219870
UR - https://www.mdpi.com/1422-0067/27/21/9870
AB - Complex molecular alterations in cancers influence tumor biology, therapeutic response, and resistance. We report a case of cutaneous melanoma demonstrating extensive intratumoral heterogeneity with important clinical implications. A 77-year-old man with stage IIA cutaneous melanoma developed an isolated nodal recurrence one year after resection. Comprehensive next-generation sequencing of the metastatic lesion revealed an uncommon genomic profile consisting of a class 3 BRAF Y472V mutation, two NF1 loss-of-function mutations, and two concurrent KIT mutations: a dominant, potentially targetable K642E mutation and a low-frequency D816V mutation associated with resistance to tyrosine kinase inhibitors. The tumor exhibited a high tumor mutational burden and microsatellite stability. The patient received neoadjuvant nivolumab plus relatlimab followed by surgical resection, achieving complete pathologic response. Repeat sequencing of the resected specimen demonstrated complete molecular clearance of all previously detected variants. This case illustrates the value of comprehensive genomic profiling in revealing biologically complex melanoma with coexisting driver and resistance-associated alterations. The presence of a treatment-naïve KIT resistance mutation suggests preexisting subclonal heterogeneity that may influence future targeted therapy, while high tumor mutational burden and NF1 loss may have contributed to the excellent response to immune checkpoint blockade.
SN - 1422-0067
ER -